000 02080nam  2200277za 4500
0019.823547
003CaOODSP
00520221107143925
007cr |||||||||||
008160902s2007    onc    |o    f|0| 0 eng d
040 |aCaOODSP|beng
043 |an-cn---
0861 |aH14-183/2007E-PDF
24500|aHorizontal evaluation of the Genomics Research and Development Initiative |h[electronic resource] : |bfinal report.
260 |a[Ottawa] : |bHealth Canada, |c2007.
300 |a[311] p. in various pagings
500 |aIssued also in French under title: Évaluation horizontale de l'Initiative de recherche et de développement en génomique : rapport final.
500 |a"December 20, 2007."
500 |a"Approved by Departmental Executive Committee -Finance, Evaluation and Accountability (DEC-FEA) Health Canada."
504 |aIncludes bibliographical references.
520 |aIn March 1998, the National Biotechnology Advisory Committee (NBAC) released a report recommending ways to position Canada as a leading global player in biotechnology by the year 2005. During the same period, the National Research Council (NRC) and the Medical Research Council (now the Canadian Institutes of Health Research) held discussions with stakeholders as part of the Canadian Biotechnology consultations. Genome research was clearly identified as an important priority for Canadian biotechnology research and development (R&D). The NBAC recommended that a top priority be placed on several actions, including political championship and increased funding to Canada's genome program. The February 1999 Budget provided $55 million in funding for genomics R&D in six departments and agencies under the Canadian Biotechnology Strategy (CBS). ...
69207|2gccst|aGenomics
69207|2gccst|aProgram assessment
7101 |aCanada. |bHealth Canada.
77508|tÉvaluation horizontale de l'Initiative de recherche et de développement en génomique |w(CaOODSP)9.823549
85640|qPDF|s849 KB|uhttps://publications.gc.ca/collections/collection_2016/sc-hc/H14-183-2007-eng.pdf